Conference abstracts

10 abstracts

• Level 3ESMO Congress 2026

  Clinical utility of ultra-sensitive ctDNA MRD monitoring in advanced NSCLC

  Srushti Borkar · Abstract 2728eP · ePoster

  PosterPoster PDF. An ASCO or ESMO member login may be required.

• Level 2prognosticASCO Annual Meeting 2025

  Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

  Reck, Martin · Abstract 8009 · AEGEAN · 168 MRD-evaluable patients at a landmark a median of 6.9 weeks after surgery; 17 (10%) MRD-positive (10 durvalumab, 7 placebo)

  patient-specific tumor-informed assays (brand not named in the abstract)

  12-month DFS was 14.3% if MRD-positive vs 89.3% if MRD-negative. MRD positivity was associated with worse DFS in both arms (durvalumab HR 21.28, 95% CI 7.70-58.83; placebo HR 14.29, 95% CI 4.94-41.36). No MRD-positive patient in the durvalumab arm had a pathologic complete or major pathologic response. DFS trends favored durvalumab especially among MRD-negative patients (HR 0.56, 95% CI 0.26-1.20). KEAP1 and KMT2C mutations were associated with MRD-positive status in the durvalumab arm in this small exploratory analysis.

• Level 2mixedESMO Congress 2025

  LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses

  Goss, G. · Abstract LBA68 · LBA · CCTG BR.31 · 1,415 randomized; MRD available in 1,131 (80%), of whom 116 (10%) were positive; median follow-up 81 months

  Invitae Personalized Cancer Monitoring (tumor-informed), tested on plasma at randomization

  Adjuvant durvalumab did not improve OS versus placebo in any prespecified analysis group (all-randomized HR 1.02, 95% CI 0.84-1.25; PD-L1 TC >=25% and EGFR/ALK-negative HR 0.98). MRD positivity was strongly prognostic for worse OS in the placebo arm (HR 6.50 to 8.74 across groups). Durvalumab improved OS among MRD-positive, EGFR/ALK-negative patients with PD-L1 TC >=25% (HR 0.30, 95% CI 0.11-0.80; P=0.011; n=29) and PD-L1 TC >=1% (HR 0.49, P=0.024; n=55); treatment-by-MRD interaction P values were all <0.05.

  SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.

• Level 2ESMO Congress 2025

  Molecular residual disease (MRD) analysis from the LAURA study of osimertinib in unresectable stage III EGFR-mutated NSCLC

  Edurne Arriola Aperribay · Abstract 1817MO · Mini oral · LAURA

  SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.

• Level 2prognosticASCO Annual Meeting 2024

  Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

  John, Tom · Abstract 8005 · ADAURA · 245 of 682 randomized patients had samples to produce MRD panels; 220 (32%) were evaluable (112 osimertinib, 108 placebo)

  RaDaR (NeoGenomics), personalized panels of up to 50 tumor-specific variants from whole-exome sequencing of resected tumor

  Baseline MRD was detected in 5/112 (4%) on osimertinib vs 13/108 (12%) on placebo; 4 of 5 became MRD-negative on osimertinib vs 0 of 13 on placebo. On-treatment MRD detection had 65% clinical sensitivity and 95% specificity for DFS events and preceded a DFS event by a median of 4.7 months. At 36 months, MRD/DFS event-free rates were 86% vs 36% (HR 0.23, 95% CI 0.15-0.36). Most MRD/DFS events on osimertinib occurred after treatment completion (19/28), 11 of those 19 within 12 months of stopping.

• Level 2ESMO Congress 2024

  IMpower010: ctDNA status and 5-year disease-free survival follow-up in resected NSCLC after adjuvant chemotherapy followed by atezolizumab or best supportive care

  Heather Wakelee · Abstract 1211P · Poster · IMpower010

  PosterPoster PDF. An ASCO or ESMO member login may be required.

• Trial in progressESMO Asia Congress 2022

  Minimal residual disease-guided adjuvant tislelizumab after adjuvant chemotherapy in resected stage IIA-IIIB NSCLC: A single-arm phase II study (Seagull)

  Feng Li · Abstract 304TiP · Poster / trial-in-progress · Seagull

  Trial in progress

  PosterPoster PDF. An ASCO or ESMO member login may be required.

• Level 2prognosticASCO Annual Meeting 2021

  Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

  Gale, Davina · Abstract 8517 · LUCID · 88 patients, 363 plasma samples; landmark analysis in 62 patients (2 weeks to 4 months after initial treatment); 69 surgery, 19 chemoradiotherapy

  RaDaR personalized tumor-informed assay (up to 48 tumor-specific variants)

  Landmark post-treatment ctDNA detection was associated with relapse (HR 20.7, 95% CI 7.7-55.5, P<0.0001). All 11 patients with landmark detection progressed, at a median of 121 days after detection, including all 8 who relapsed within 300 days of treatment. Among 27 patients who progressed, post-treatment ctDNA was detected in 17, with a median lead time of 203 days (up to 741 days).

• Level 3prognosticASCO Annual Meeting 2021

  Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.

  Kurtz, David Matthew · Abstract 8518 · Personalized PhasED-Seq applied in 5 patients with localized NSCLC (14 plasma samples); methodologic series

  PhasED-Seq (personalized phased-variant sequencing after tumor/normal whole-genome sequencing)

  Phased variants had a lower background rate than SNVs, including duplex SNVs (1.2e-6 vs 3.8e-5 and 1.0e-5). PhasED-Seq detected all 5 SNV-positive samples and 5 additional samples at tumor fractions as low as 0.000094%. In one patient with stage III adenocarcinoma, PhasED-Seq detected MRD in three on-treatment samples that were undetectable by SNVs, including a sample 8 months before progression.

• Level 2prognosticESMO Immuno-Oncology Congress 2021

  2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

  Zhou, C. · Abstract 2O · oral · IMpower010 · 600 ctDNA-evaluable of 1,005 randomized; 534 with stage II-IIIA disease

  Natera Signatera RUO (plasma after surgery and before adjuvant chemotherapy)

  ctDNA positivity rose with stage (IB 9%, II 14%, IIIA 29%) and was associated with worse DFS. In stage II-IIIA disease, atezolizumab improved DFS versus BSC in both ctDNA-positive and ctDNA-negative patients, with clearer benefit when PD-L1 TC was >=1% (ctDNA-negative HR 0.57, 95% CI 0.36-0.90; ctDNA-positive HR 0.54, 95% CI 0.31-0.93). Among PD-L1 TC <1% patients, HRs were 0.95 (ctDNA-negative) and 0.88 (ctDNA-positive).